We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

70 hedge funds and large institutions have $116M invested in Invesco Biotechnology & Genome ETF in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $113M → $116M (+$2.43M)

0.52% less ownership

Funds ownership: 29.56% → 29.04% (-0.52%)

5% less funds holding

Funds holding: 74 → 70 (-4)

10% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 20

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
70
Holders Change
-4
Holders Change %
-5.41%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
18
Reduced
20
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BWP
Baldwin Wealth Partners
Massachusetts
+$1.49M
2
NDSI
Newman Dignan & Sheerar Inc
Rhode Island
+$1.28M
3
MCM
Murphy Capital Management
New Jersey
+$233K
4
GT
Glenmede Trust
Pennsylvania
+$165K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$154K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.62M
2
VKH
Virtu KCG Holdings
New York
-$1.58M
3
Goldman Sachs
Goldman Sachs
New York
-$1.18M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$823K
5
Bank of America
Bank of America
North Carolina
-$617K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$614K +$37K +822 +7%
BPC
27
Banque Pictet & Cie
Switzerland
$545K – – –
Janney Montgomery Scott
28
Janney Montgomery Scott
Pennsylvania
$481K +$19.8K +439 +4%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$474K -$823K -18,272 -64%
MAA
30
Managed Account Advisors
New Jersey
$474K -$12.3K -272 -3%
B
31
Baird
Wisconsin
$414K +$138K +3,056 +52%
CAN
32
Cetera Advisor Networks
California
$409K +$58.7K +1,302 +17%
Verition Fund Management
33
Verition Fund Management
Connecticut
$396K +$75.1K +1,668 +24%
Citigroup
34
Citigroup
New York
$385K -$1.89K -42 -0.5%
OIA
35
Optimum Investment Advisors
Illinois
$381K +$33.8K +750 +10%
ONB
36
Old National Bancorp
Indiana
$376K – – –
IAA
37
Ironsides Asset Advisors
North Carolina
$368K – – –
Neuberger Berman Group
38
Neuberger Berman Group
New York
$350K -$33.8K -750 -9%
OC
39
Oppenheimer & Co
New York
$339K +$23.7K +526 +8%
NPC
40
National Planning Corporation
California
$327K +$41.8K +928 +15%
JIC
41
Joel Isaacson & Co
New York
$318K – – –
CIC
42
Carnegie Investment Counsel
Ohio
$317K +$22.7K +505 +8%
PJSIMP
43
P.J. Schmidt Investment Management (PJS)
Wisconsin
$309K – – –
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$273K +$2.61K +58 +1%
MCM
45
Murphy Capital Management
New Jersey
$238K +$233K +5,170 New
MFS
46
MSI Financial Services
Massachusetts
$235K +$120K +2,665 +110%
GT
47
Glenmede Trust
Pennsylvania
$168K +$165K +3,669 New
Ameriprise
48
Ameriprise
Minnesota
$158K +$50.9K +1,130 +49%
WEC
49
Winslow Evans & Crocker
Massachusetts
$141K -$8.29K -184 -6%
Canada Life
50
Canada Life
Manitoba, Canada
$81K – – –
1
2
3 4

PBE Hedge Fund Activity: Q3 2014 in Review

70 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2014, worth a combined $116M — up 2.1% from $113M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PBE and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 18 added.

The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.49M. The largest seller was Morgan Stanley, cutting an estimated $1.62M.

  • 70 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2014, down from 74 in Q2 2014.
  • Funds reported $116M of Invesco Biotechnology & Genome ETF stock for Q3 2014, up 2.1% quarter-over-quarter.
  • 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2014 and 11 closed out, a net change of -4 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q3 2014 was Baldwin Wealth Partners, an estimated $1.49M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q3 2014 was Morgan Stanley, an estimated $1.62M sold.

Based on aggregated 13F filings for Q3 2014.